Trial Profile
A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2014
Price :
$35
*
At a glance
- Drugs Eritoran (Primary)
- Indications Sepsis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 05 Dec 2014 New trial record